Amgen Inc. (AMGN) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
AMGN Revenue Growth
Revenue Breakdown (FY 2025)
AMGN's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
AMGN Revenue Analysis (2014–2025)
As of May 6, 2026, Amgen Inc. (AMGN) generated trailing twelve-month (TTM) revenue of $37.24 billion, reflecting solid growth of +5.8% year-over-year. The most recent quarter (Q1 2026) recorded $8.62 billion in revenue, down 12.9% sequentially.
Looking at the longer-term picture, AMGN's 5-year compound annual growth rate (CAGR) stands at +7.6%, indicating steady revenue expansion. The company achieved its highest annual revenue of $36.74 billion in 2025, representing a new all-time high.
Revenue diversification analysis shows AMGN's business is primarily driven by Other Products (21%), Prolia (12%), and Repatha (9%).
When compared to Healthcare sector peers including GILD (+2.4% YoY), BIIB (+0.4% YoY), and REGN (+5.9% YoY), AMGN has underperformed the peer group in terms of revenue growth. Compare AMGN vs GILD →
AMGN Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| AMGNCurrent | $37.2B | +5.8% | +7.6% | 29.1% | |
 GILD | $28.8B | +2.4% | +5.1% | 5.8% | |
 BIIB | $9.8B | +0.4% | -6.1% | 19.1% | |
 REGN | $14.3B | +5.9% | +11.0% | 24.9% | |
 VRTX | $12.1B | +10.4% | +14.2% | 39.4% | |
 BMY | $48.2B | +1.8% | +2.5% | 26.3% |
AMGN Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $36.74B | +9.9% | $26.01B | 70.8% | $10.68B | 29.1% |
| 2024 | $33.42B | +18.6% | $20.57B | 61.5% | $7.26B | 21.7% |
| 2023 | $28.19B | +7.1% | $19.77B | 70.1% | $7.90B | 28.0% |
| 2022 | $26.32B | +1.3% | $19.92B | 75.7% | $9.57B | 36.3% |
| 2021 | $25.98B | +2.2% | $19.52B | 75.2% | $7.64B | 29.4% |
| 2020 | $25.42B | +8.8% | $19.27B | 75.8% | $9.14B | 35.9% |
| 2019 | $23.36B | -1.6% | $19.01B | 81.4% | $9.67B | 41.4% |
| 2018 | $23.75B | +3.9% | $19.65B | 82.7% | $10.26B | 43.2% |
| 2017 | $22.85B | -0.6% | $18.78B | 82.2% | $9.97B | 43.6% |
| 2016 | $22.99B | +6.1% | $18.83B | 81.9% | $9.79B | 42.6% |
Full AMGN Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
Should I Buy AMGN Right Now?
Bull case, key risks, Wall St analyst verdict, and what council investors are saying — updated daily.
See AMGN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs AMGN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare AMGN vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonAMGN — Frequently Asked Questions
Quick answers to the most common questions about buying AMGN stock.
Is AMGN's revenue growth accelerating or slowing?
AMGN maintains +5.8% revenue growth, in line with its 5-year CAGR of +7.6%. TTM revenue stands at $37.2B. Growth rate remains consistent with historical average.
What is AMGN's long-term revenue growth rate?
Amgen Inc.'s 5-year revenue CAGR of +7.6% reflects the sustained expansion pattern. Current YoY growth of +5.8% is near this long-term average.
How is AMGN's revenue distributed by segment?
AMGN reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.